Home

Resultados 1 - 10 de 178,025 para marketed. La búsqueda tomó 3.71 segundos.  
Ordenar por fecha/Ordenar por relevancia
Producción | Manejo integrado de plagas y plaguicidas | Organización de las Naciones Unidas para la Alimentación y la Agricultura | IPM and Pesticide Risk Reduction | Food and Agriculture Organization of the United Nations FAO.org العربية 中文 english français Русский Español Manejo integrado de plagas y plaguicidas Acerca de Manejo integrado de plagas Gestión de plaguicidas Normas y directrices Recursos Socios Noticias Código internacional de conducta para el manejo de plaguicidas Políticas y legislación Producción Registro Control de calidad Comercio Envasado, etiquetado y publicidad Distribución y venta Utilización Inocuidad alimentaria, salud y vigilancia ambiental Gestión de residuos relacionados con los plaguicidas Tratamiento de plaguicidas altamente peligrosos (HHP) Reducción de riesgos e integración de la biodiversidad en la agricultura Escuelas de Campo de Agricultores Gestión de residuos relacionados con los plaguicidas Resistencia a los antimicrobianos Production The pesticide production should meet the requirements of the International Code of Conduct on Pesticide Management to: ensure that technical grade and formulated pesticide products conform with applicable national standards or FAO specifications for agricultural pesticides, and with WHO specifications for public health pesticides, when available; ensure that the active ingredient and co-formulants of pesticide products being marketed correspond in identity, quality, purity and composition to the ingredients of the registered pesticide product that have been tested, evaluated and cleared for toxicological and environmental acceptability.
Idioma:Español
Puntuación: 1447634.4 - https://www.fao.org/pest-and-p...-de-plaguicidas/production/es/
Fuente de datos: un
REPORT OF THE SPECIAL RAPPORTEUR ON THE IMPLICATIONS FOR HUMAN RIGHTS OF THE ENVIRONMENTALLY SOUND MANAGEMENT AND DISPOSAL OF HAZARDOUS SUBSTANCES AND WASTES ON HIS MISSION TO THE REPUBLIC OF KOREA : NOTE / BY THE SECRETARIAT
During his visit, the Special Rapporteur was deeply disturbed by the case of “humidifier sterilizers” marketed and sold to consumers in the Republic of Korea without adequate investigation of their risks to human health and life.29 As of December 2015, the Government had recognized that 95 people had died and 221 had suffered adverse health impacts after inhaling hazardous chemicals which were added to humidifier water tanks and then dispersed through the humidifier inside a home environment. The chemical mixture was marketed on the premise that it would promote health and well-being. (...) Oxy Sak Sak accounted for 60-80 per cent of the market.30 Fourteen different types of humidifier sterilizers were manufactured and sold from the 1990s until a mandatory recall in 2011.
Idioma:Español
Puntuación: 703434.1 - https://daccess-ods.un.org/acc...en&DS=A/HRC/33/41/ADD.1&Lang=S
Fuente de datos: ods
REPORT OF THE SPECIAL RAPPORTEUR ON THE IMPLICATIONS FOR HUMAN RIGHTS OF THE ENVIRONMENTALLY SOUND MANAGEMENT AND DISPOSAL OF HAZARDOUS SUBSTANCES AND WASTES ON HIS MISSION TO GERMANY : NOTE / BY THE SECRETARIAT
Germany is the largest chemical producing country in Europe, the world’s fourth largest chemical market (after China, the United States of America and Japan) and is home to BASF, the biggest chemical company in the world, and Bayer, which at time of writing was bidding to purchase Monsanto, the multinational agrochemical. (...) It also contains numerous precautionary aspects, recognizing the vast uncertainties arising from the failure to require companies to generate and make available health and safety information for tens of thousands of industrial chemicals on the market today. A specialized agency, the European Chemicals Agency, was created to help manage the implementation of REACH. 11. (...) This pragmatic requirement, known as “no-data, no-market”, shifts the burden of proof away from public authorities and onto relevant businesses.
Idioma:Español
Puntuación: 703434.1 - https://daccess-ods.un.org/acc...en&DS=A/HRC/33/41/ADD.2&Lang=S
Fuente de datos: ods
LETTER DATED 2006/10/13 FROM THE PERMANENT REPRESENTATIVE OF FRANCE TO THE UNITED NATIONS ADDRESSED TO THE PRESIDENT OF THE SECURITY COUNCIL
Excluding botulinum toxins and Oonotoxins in product form meeting all of the following criteria: • are pharmaceutical formulations designed for testing and human dministration in the treatment of medical conditions; • are pre-packaged for distribution as clinical or medical products; and • are authorised by a state authority to be marketed as clinical or medical products. S/2006/816 06-57427 16 Genetic Elements and Genetically-modified Organisms: G1 Genetic elements that contain nucleic acid sequences associated with the pathogenicity of any of the microorganisms in the list.
Idioma:Español
Puntuación: 696567.3 - daccess-ods.un.org/acce.../get?open&DS=S/2006/816&Lang=S
Fuente de datos: ods
LETTER DATED 29 MARCH 2021 FROM THE PERMANENT REPRESENTATIVE OF YEMEN TO THE UNITED NATIONS ADDRESSED TO THE PRESIDENT OF THE SECURITY COUNCIL
S/2021/304 8/24 21-04250 Introduction After the Houthi militia’s coup against the legitimate authority in Yemen on September 21, 2014, the militia marketed itself as a counter-terrorism force, hoping that the international community would deal with it and recognize it and continued to fabricate excuses and lies, accusing the charge of terrorism pinning it on anyone who stand in their way, taking advantage of the international directive to combat terrorism.
Idioma:Español
Puntuación: 663743.07 - https://daccess-ods.un.org/acc.../get?open&DS=S/2021/304&Lang=S
Fuente de datos: ods
LETTER DATED 16 APRIL 2012 FROM THE PERMANENT REPRESENTATIVE OF THE UNITED STATES OF AMERICA TO THE UNITED NATIONS ADDRESSED TO THE SECRETARY-GENERAL
[4] Excluding botulinum toxins and conotoxins in product form meeting all of the following criteria: o are pharmaceutical formulations designed for testing and human administration in the treatment of medical conditions; o are pre-packaged for distribution as clinical or medical products; and o are authorised by a state authority to be marketed as clinical or medical products. Genetic Elements and Genetically-modified Organisms: 1.
Idioma:Español
Puntuación: 606576.07 - https://daccess-ods.un.org/acc.../get?open&DS=S/2012/236&Lang=S
Fuente de datos: ods
REGIONAL TRAINING WORKSHOPS ON THE PREPARATION OF BIENNIAL UPDATE REPORTS FROM NON-ANNEX I PARTIES. REPORT BY THE SECRETARIAT
GE.16-15791 (S) 280916 041016  Órgano Subsidiario de Ejecución 45º período de sesiones Marrakech, 7 a 14 de noviembre de 2016 Tema 4 b) del programa
Idioma:Español
Puntuación: 581532.8 - daccess-ods.un.org/acce...pen&DS=FCCC/SBI/2016/15&Lang=S
Fuente de datos: ods
NOTE VERBALE DATED 6 FEBRUARY 2017 FROM THE PERMANENT MISSION OF THE RUSSIAN FEDERATION TO THE UNITED NATIONS ADDRESSED TO THE CHAIR OF THE COMMITTEE : SECURITY COUNCIL COMMITTEE ESTABLISHED PURSUANT TO RESOLUTION 1718 (2006)
Technical note: the functionality specified in paragraph 4 above may be met by certain equipment, described or marketed as generators, electronic test equipment, alternating current (AC) power supplies, variable speed motor drives or variable frequency drives. 5.
Idioma:Español
Puntuación: 581532.8 - https://daccess-ods.un.org/acc....49/2016/19/ADD.1/REV.1&Lang=S
Fuente de datos: ods
REPORT OF THE SPECIAL RAPPORTEUR ON THE RIGHT TO FOOD, OLIVIER DE SCHUTTER :ADDENDUM
First, an estimated 35,000 large-scale commercial farmers, predominantly of white origin, own farms with an average size of 2,500 hectares, according to Agri South Africa (Agri SA).30 These farmers produce 95 per cent of all marketed outputs. They collectively occupied 87 per cent of the agricultural land in 2003,31 and there is no indication that this figure has significantly changed since then. (...) Under the Restitution of Land Rights Act (Act No. 22 of 1994), communities dispossessed of their land after 1913 can file a claim with the Land Claims Commission; the Government then pays the current occupier the market price for the land, which is given back to the communities concerned. (...) It is aimed at: (a) immediately reducing poverty among groups that are not expected to fully participate in the labour market and thus are vulnerable to low income (older persons, children, and persons with disabilities); and (b) increasing investment in health, education and nutrition. 42.
Idioma:Español
Puntuación: 466077.54 - https://daccess-ods.un.org/acc...en&DS=A/HRC/19/59/ADD.3&Lang=S
Fuente de datos: ods
REPORT OF THE SPECIAL RAPPORTEUR ON THE RIGHT OF EVERYONE TO THE ENJOYMENT OF THE HIGHEST ATTAINABLE STANDARD OF PHYSICAL AND MENTAL HEALTH, ANAND GROVER
Crucially, the company may not market the medicine to social group A (i.e. wealthy urban elites), with little or no attempt to reach social groups B-E. (...) As soon as the new medicine is marketed at higher prices (usually in high-income countries), the patent holder has a right-to-health responsibility to put in place a range of mechanisms, such as differential pricing between and within countries, to enhance access for those who cannot afford those prices. (...) At its peak, the company held a 40% global market share in ARVs; today, it has a global market share of approximately 20%. 49.
Idioma:Español
Puntuación: 466077.54 - daccess-ods.un.org/acce...en&DS=A/HRC/11/12/ADD.2&Lang=S
Fuente de datos: ods